

The Tablets, Ring, Injections as Options (<scp>TRIO</scp>  
women chose and used for future <scp>HIV</scp> and p

Journal of the International AIDS Society

21, e25094

DOI: [10.1002/jia2.25094](https://doi.org/10.1002/jia2.25094)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Perceptions of the “Fabrica” An exploratory study of a novel multi-purpose technology among women in Sub Saharan Africa. PLoS ONE, 2018, 13, e0204821.	2.5	16
2	Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda. PLoS ONE, 2018, 13, e0207650.	2.5	24
3	&p&t;Engaging study participants in interpreting results: lessons from the TRIO study in Kenya and South Africa&t;/p&t;. International Journal of Women’s Health, 2019, Volume 11, 395-403.	2.6	8
4	Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP). Pharmaceutics, 2019, 11, 315.	4.5	62
5	HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. Journal of the International AIDS Society, 2019, 22, e25298.	3.0	150
6	Vaginal ring acceptability and related preferences among women in low- and middle-income countries: A systematic review and narrative synthesis. PLoS ONE, 2019, 14, e0224898.	2.5	53
7	Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076). Journal of the International AIDS Society, 2019, 22, e25408.	3.0	33
8	Two Birds with One Stone: Health Care Providers’s Perspectives about Prevention Technologies in Kenya and South Africa. Journal of the International Association of Providers of AIDS Care, 2019, 18, 232595821984136.	1.5	9
9	End-user preference for and choice of four vaginally delivered <sc>HIV</sc> prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study. Journal of the International AIDS Society, 2019, 22, e25283.	3.0	46
10	A Qualitative Systematic Review of Women’s Experiences Using Contraceptive Vaginal Rings: Implications for New Technologies. Perspectives on Sexual and Reproductive Health, 2019, 51, 71-80.	3.3	9
11	&p&t;&ldquo;We are not the same&rdquo;: African women’s view of multipurpose prevention products in the TRIO clinical study&t;/p&t;. International Journal of Women’s Health, 2019, Volume 11, 97-107.	2.6	33
12	Design of an Implant for Long-Acting HIV Pre-Exposure Prophylaxis: Input from South African Health Care Providers. AIDS Patient Care and STDs, 2019, 33, 157-166.	2.5	16
13	Insights for Implementation Science From 2 Multiphased Studies With End-Users of Potential Multipurpose Prevention Technology and HIV Prevention Products. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, S222-S229.	2.1	19
14	Young Women’s Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 394-403.	2.1	69
15	Mosaic effectiveness: measuring the impact of novel PrEP methods. Lancet HIV, the, 2019, 6, e800-e806.	4.7	15
16	Next-Generation Preexposure Prophylaxis: Choices For Effective HIV Prevention. Journal of Infectious Diseases, 2020, 221, 1387-1389.	4.0	3
17	Hygiene, Blood Flow, and Vaginal Overload: Why Women Removed an HIV Prevention Vaginal Ring During Menstruation in Malawi, South Africa, Uganda and Zimbabwe. AIDS and Behavior, 2020, 24, 617-628.	2.7	17
18	Perspectives from Young South African and Zimbabwean Women on Attributes of Four (Placebo) Vaginal Microbicide Delivery Forms. AIDS and Behavior, 2020, 24, 637-647.	2.7	9

#	ARTICLE	IF	CITATIONS
19	Long-acting injectable cabotegravir for the prevention of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 19-26.	3.8	71
20	Topical delivery of long-acting antiretrovirals to prevent HIV acquisition. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 42-48.	3.8	12
21	The only way is up. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 73-80.	3.8	13
22	An open-label, randomized crossover study to evaluate the acceptability and preference for contraceptive options in female adolescents, 15 to 19 years of age in Cape Town, as a proxy for HIV prevention methods (UChoose). <i>Journal of the International AIDS Society</i> , 2020, 23, e25626.	3.0	26
23	Estimating the market size for a dual prevention pill: adding contraception to pre-exposure prophylaxis (PrEP) to increase uptake. <i>BMJ Sexual and Reproductive Health</i> , 2021, 47, 166-172.	1.7	9
24	Contraception as a Potential Gateway to Pre-Exposure Prophylaxis: US Women's Pre-Exposure Prophylaxis Modality Preferences Align with Their Birth Control Practices. <i>AIDS Patient Care and STDs</i> , 2020, 34, 132-146.	2.5	18
25	Preferences for long-acting Pre-Exposure Prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment. <i>Journal of the International AIDS Society</i> , 2020, 23, e25528.	3.0	49
26	The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study. <i>Journal of Infectious Diseases</i> , 2021, 224, 1179-1186.	4.0	19
27	Towards a roadmap to advance non-hormonal contraceptive multipurpose prevention technologies: strategic insights from key stakeholders. <i>Biology of Reproduction</i> , 2020, 103, 289-298.	2.7	13
28	Giving voice to the end-user: input on multipurpose prevention technologies from the perspectives of young women in Kenya and South Africa. <i>Sexual and Reproductive Health Matters</i> , 2021, 29, 246-260.	1.8	14
29	Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. <i>Lancet HIV</i> , 2021, 8, e87-e95.	4.7	70
30	Impact of Women's Home Environment on Use of the Dapivirine Vaginal Ring for HIV Prevention in Sub-Saharan Africa. <i>AIDS and Behavior</i> , 2021, 25, 3847-3857.	2.7	2
31	The Promise of the Dual Prevention Pill: A Framework for Development and Introduction. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	1.9	14
32	Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 409-420.	1.1	20
33	Multipurpose Prevention Technologies: Oral, Parenteral, and Vaginal Dosage Forms for Prevention of HIV/STIs and Unplanned Pregnancy. <i>Polymers</i> , 2021, 13, 2450.	4.5	12
34	Contraceptive Method Mix and HIV Risk Behaviors Among Kenyan Adolescent Girls and Young Women Seeking Family Planning Services: Implications for Integrating HIV Prevention. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	1.9	2
35	Pills, Injections, Rings, or Implants? PrEP Formulation Preferences of PrEP-Experienced African Women for HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, e30-e32.	2.1	9
36	Multipurpose Prevention Technologies: Opportunities and Challenges to Ensure Advancement of the Most Promising MPTs. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	1.9	14

#	ARTICLE	IF	CITATIONS
37	Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113849.	13.7	29
38	Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments. <i>Clinical Infectious Diseases</i> , 2022, 75, 3-10.	5.8	4
39	Vaginal ring acceptability: A systematic review and meta-analysis of vaginal ring experiences from around the world. <i>Contraception</i> , 2022, 106, 16-33.	1.5	15
40	Adolescent girls and young women's PrEP-user journey during an implementation science study in South Africa and Kenya. <i>PLoS ONE</i> , 2021, 16, e0258542.	2.5	67
41	A Qualitative Systematic Review of Women's Experiences Using Contraceptive Vaginal Rings: Implications for New Technologies. <i>International Perspectives on Sexual and Reproductive Health</i> , 2019, 45, 25-34.	3.7	2
42	"œI felt like a TRIO champion" end-user perspectives on their role as co-designers of multi-purpose technologies. <i>Gates Open Research</i> , 2020, 4, 163.	1.1	5
43	The use of objective adherence measures targeting four placebo microbicide delivery forms in the Quatro Clinical Crossover Study. <i>Clinical and Translational Discovery</i> , 2021, 1, e13.	0.5	0
44	Preferences for HIV Preexposure Prophylaxis Products Among Black Women in the U.S.. <i>AIDS and Behavior</i> , 2022, 26, 2212-2223.	2.7	18
45	Drug-releasing vaginal rings for HIV/STI and pregnancy prevention: a review of recent advances and clinical applications. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 47-58.	5.0	4
46	The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United States. <i>AIDS Research and Therapy</i> , 2022, 19, 13.	1.7	2
47	Promises and challenges: cabotegravir for preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 186-191.	3.8	7
48	HIV Pre-exposure Prophylaxis Implant Stated Preferences and Priorities: Results of a Discrete Choice Experiment Among Women and Adolescent Girls in Gauteng Province, South Africa. <i>AIDS and Behavior</i> , 2022, 26, 3099-3109.	2.7	7
49	Acceptability of a Long-Acting, Multipurpose Vaginal Ring: Findings from a Phase I Trial in the U.S. and Dominican Republic. <i>Journal of Women's Health</i> , 2022, 31, 1343-1352.	3.3	5
50	Mapping Interests in Event-Driven and Long-Acting Pre-exposure Prophylaxis Formulations onto the HIV Risk Environment of Street-Based Female Sex Workers: A Latent Class Analysis. <i>AIDS and Behavior</i> , 2022, 26, 1992-2002.	2.7	3
51	Female and male partner perspectives on placebo Multipurpose Prevention Technologies (MPTs) used by women in the TRIO study in South Africa and Kenya. <i>PLoS ONE</i> , 2022, 17, e0265303.	2.5	5
52	Couples' Preferences for "2 in 1" Multipurpose Prevention Technologies to Prevent Both HIV and Pregnancy: Results of a Discrete Choice Experiment in Uganda and Zimbabwe. <i>AIDS and Behavior</i> , 0, , .	2.7	10
53	Barriers and Enablers Influencing Women's Adoption and Continuation of Vaginally Inserted Contraceptive Methods: A Literature Review. <i>Studies in Family Planning</i> , 0, , .	1.8	2
54	U.S. Women Need the Dapivirine Ring, Too: FDA as Structural Barrier to HIV Prevention for Women. <i>AIDS Education and Prevention</i> , 2022, 34, 311-324.	1.1	2

#	ARTICLE	IF	CITATIONS
55	Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial. <i>AIDS and Behavior</i> , 0, , .	2.7	0
56	Making the Case for Joint Decision-Making in Future Multipurpose Prevention Technology (MPT) Choice: Qualitative Findings on MPT Attribute Preferences from the CUPID Study (MTN-045). <i>Journal of the International AIDS Society</i> , 2022, 25, .	3.0	2
59	Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection. <i>Nature Communications</i> , 2023, 14, .	12.8	6
60	Women Want Choices: Opinions from the Share.Learn.Shape Global Internet Survey About Multipurpose Prevention Technology (MPT) Products in Development. <i>AIDS and Behavior</i> , 2023, 27, 2190-2204.	2.7	8
61	Microarray patch for HIV prevention and as a multipurpose prevention technology to prevent HIV and unplanned pregnancy: an assessment of potential acceptability, usability, and programmatic fit in Kenya. <i>Frontiers in Reproductive Health</i> , 0, 5, .	1.9	5
62	Prospective acceptability of a multipurpose technology (MPT) implant in preclinical development to prevent HIV and unplanned pregnancy: Qualitative insights from women end users and health care providers in South Africa and Zimbabwe. <i>PLoS ONE</i> , 2023, 18, e0285711.	2.5	1
63	Optimizing the pipeline of multipurpose prevention technologies: opportunities across women's reproductive lifespans. <i>Frontiers in Reproductive Health</i> , 0, 5, .	1.9	4
64	Synthesis of end-user research to inform future multipurpose prevention technologies in sub-Saharan Africa: a scoping review. <i>Frontiers in Reproductive Health</i> , 0, 5, .	1.9	2
65	Commentary: Multipurpose prevention technologies—What about sexually transmitted infections?. <i>Frontiers in Reproductive Health</i> , 0, 5, .	1.9	0
66	Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study). <i>PLoS ONE</i> , 2023, 18, e0287525.	2.5	2
67	Equipping providers to offer novel MPTs: Developing counseling messages for the Dual Prevention Pill in clinical studies and beyond. <i>Frontiers in Reproductive Health</i> , 0, 5, .	1.9	2
68	Preferences and acceptability for long-acting PrEP agents among pregnant and postpartum women with experience using daily oral PrEP in South Africa and Kenya. <i>Journal of the International AIDS Society</i> , 2023, 26, .	3.0	3
69	Strategic actions to advance multipurpose prevention technologies in low- and middle-income countries. <i>Frontiers in Reproductive Health</i> , 0, 5, .	1.9	2
70	Participant experiences with a multipurpose vaginal ring for HIV and pregnancy prevention during a phase 1 clinical trial: learning from users to improve acceptability. <i>Frontiers in Reproductive Health</i> , 0, 5, .	1.9	0
71	Next generation 3D-printed intravaginal ring for prevention of HIV and unintended pregnancy. <i>Biomaterials</i> , 2023, 301, 122260.	11.4	2
72	Exploring user and stakeholder perspectives from South Africa and Uganda to refine microarray patch development for HIV PrEP delivery and as a multipurpose prevention technology. <i>PLoS ONE</i> , 2023, 18, e0290568.	2.5	1
73	Biomedical, socio-behavioral, and implementation science gaps in multipurpose prevention technology research. <i>Frontiers in Reproductive Health</i> , 0, 5, .	1.9	0
74	Long-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy. <i>Journal of Controlled Release</i> , 2023, 363, 606-620.	9.9	0

#	ARTICLE	IF	CITATIONS
75	â€œItâ€™s already in your body and itâ€™s preventingâ€ a qualitative study of African female adolescentsâ€™ acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa. BMC Public Health, 2023, 23, .	2.9	0
76	Two into one does go: Formulation development of a multipurpose combination vaginal ring releasing dapivirine and metronidazole for prevention of HIV infection and treatment of bacterial vaginosis. International Journal of Pharmaceutics, 2023, 648, 123572.	5.2	1
77	Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women using the Dapivirine Vaginal Ring. Journal of Infectious Diseases, 0, , .	4.0	0
78	Creating allies: qualitative exploration of young womenâ€™s preferences for PrEP methods and parentsâ€™ role in PrEP uptake and user support in urban and rural Zambia. BMC Women's Health, 2024, 24, .	2.0	0
79	End-user research into understanding perceptions of and reactions to a microarray patch (MAP) for contraception among women in Ghana, Kenya and Uganda. Frontiers in Reproductive Health, 0, 6, .	1.9	0
80	Assessing the acceptability of, adherence to and preference for a dual prevention pill (DPP) for HIV and pregnancy prevention compared to oral pre-exposure prophylaxis (PrEP) and oral contraception taken separately: protocols for two randomised, controlled, cross-over studies in South Africa and Zimbabwe. BMI Open, 2024, 14, e075381.	1.9	0